Skip to main content
ARDTArdent Health, Inc.Sell5.9·$10.91+0.83%
SellModerate Confidence
Investment thesis

A perfect four-quarter earnings beat streak averaging nearly 60% above estimates, a forward multiple of 7.2x with a PEG of 0.18, and analyst consensus implying 31% upside build a compelling fundamental case — tempered by a confirmed price downtrend, an unusually elevated put/call ratio, and a spot reward-to-risk ratio that narrowly misses the entry threshold.

Thesis pillars

  • Perfect Earnings Beat StreakStable
  • Deep Value Analyst ConvictionStable
  • Confirmed Downtrend In PriceStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Ardent Health, Inc. (ARDT) Stock Analysis

Recovery setup · Inst Constrain edge

SellModerate Confidence

Healthcare · Medical Care Facilities

Sell if holding. Engine safety override at $10.91: Risk below floor (2.7 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 11%; Elevated put/call ratio: 4.00.

Ardent Health operates 30 acute care hospitals and more than 280 additional sites of care across eight mid-sized urban markets in Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas, often through majority-owned joint ventures with academic medical centers, non-profit... Read more

$10.910.0% A.UpsideScore 5.9/10#7 of 36 Medical Care Facilities
QualityF-score8 / 9FCF yield7.55%
Stop $10.05Target $10.81(resistance)A.R:R -0.1:1
Analyst target$12.32+12.9%11 analysts
$10.81our TP
$10.91price
$12.32mean
$9
$14

Sell if holding. Engine safety override at $10.91: Risk below floor (2.7 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 11%; Elevated put/call ratio: 4.00. Chart setup: Death cross but MACD improving, RSI 74. Score 5.9/10, moderate confidence.

Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About Ardent Health, Inc.

About Ardent Health, Inc.

Ardent Health operates 30 acute care hospitals and more than 280 additional sites of care across eight urban markets in Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas, serving roughly 17,000 patients daily and 1.2 million unique patients with more than 6.1 million visits in 2025. Private third-party payors accounted for 44.3% of Ardent's revenue in 2025, up slightly from 43.5% in 2024, with the remainder derived largely from Medicare and Medicaid.

Ardent runs 18 of its 30 hospitals through majority-owned joint ventures with academic medical centers, not-for-profit health systems, and physician groups, retaining majority economic and governance control while partners hold minority stakes and, in several cases, veto rights tied to maintaining 501(c)(3) community-benefit status. Revenue comes from inpatient and ambulatory care, including 188 primary and specialty clinics, 45 urgent care centers, and four ambulatory surgery centers, billed to Medicare, Medicaid, and private commercial payors under negotiated in-network contracts. The company holds the leading or second-leading inpatient market share in most of its markets, led by Hackensack Meridian Medical Centers in New Jersey at 51.7% share and BSA Health System in Amarillo, Texas at 53.6% share, and has invested nearly $32.7 million over three years in technology, including a system-wide Epic electronic health record platform and AI-based patient-monitoring wearables.

Show full overview

Ardent's facilities are heavily concentrated in Texas and Oklahoma, home to 21 of its 30 hospitals, leaving the system exposed to state-level Medicaid assessment changes, regional labor-cost swings, and severe-weather disruption in a way a more geographically dispersed peer would not be. That concentration compounds a structural governance constraint: 18 of Ardent's hospitals operate through joint ventures where partner-appointed directors hold block-voting rights and, in several agreements, unilateral authority to terminate the management services agreement if Ardent's operations are seen as jeopardizing a partner's nonprofit community-benefit status, meaning Ardent's day-to-day operating control over a majority of its hospital count is contractually conditioned rather than absolute.

See also: Healthcare · Medical Care Facilities

From Ardent Health, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-07
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Aug 11, 202637d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Target reached (-0.9% upside)
Risk below floor (2.7 < 3.0)

Key Metrics

P/E (TTM)11.4
P/E (Fwd)8.2
Mkt Cap$1.5B
EV/EBITDA7.2
Profit Mgn2.1%
ROE13.9%
Rev Growth7.0%
Beta
DividendNone
Rating analysts18

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C4.00bearish
IV109%elevated
Max Pain$5-54.2% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMGeographicTexas and Oklahoma
    10-K Item 1A: 'our facilities are heavily concentrated in Texas and Oklahoma, which makes us sensitive to regulatory, economic and competitive conditions and changes in those states'
  • MEDIUMCustomerprivate third party payors44%
    10-K Item 1A: 'Revenues derived from private third party payors accounted for 44.3% and 43.5% of our revenues for 2025 and 2024, respectively.'

Material Events(8-K, last 90d)

  • 2026-06-02Item 5.02MEDIUM
    President and CEO Martin J. Bonick departed effective June 2, 2026; the Board immediately appointed COO Dave Caspers as President and CEO and a director, a clean handoff with an internal successor named the same day.
    SEC filing →
  • 2026-06-30Item 5.02LOW
    Follow-up filing disclosing that departed CEO Martin J. Bonick entered a Separation Agreement on June 26, 2026 providing severance benefits consistent with a termination without Cause, formalizing the previously disclosed departure.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.1
Support Resistance
0.8
52w Position
4.0

Risk profile below the gate floor. Component breakdown shows what dragged the score down.static

Put Call
0.0
Implied Vol
0.0
Volatility
2.5
Max Pain Risk
3.0
Days To Cover
4.4
Debt Equity
4.4
Short Interest
4.5
Elevated put/call: 4.00High IV: 109%Above max pain $5Concentration risks: 2 MED (10-K Item 1A)
GatesA.R:R -0.1=NEGATIVEDeath cross (50MA < 200MA)Executive change: officer departure/appointmentMomentum 6.5>=5.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 37d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
74 · Overbought
20D MA 50D MA 200D MADEATH CROSSSupport $8.23Resistance $11.03

Price Targets

$10
$11
A.Upside-0.9%
A.R:R-0.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-0.9% upside)
! Risk below floor (2.7 < 3.0)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-11 (37d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ARDT stock a buy right now?

Sell if holding. Engine safety override at $10.91: Risk below floor (2.7 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 11%; Elevated put/call ratio: 4.00. Chart setup: Death cross but MACD improving, RSI 74. Prior stop was $10.05. Score 5.9/10, moderate confidence.

What is the ARDT stock price target?

Take-profit target: $10.81 (0.0% upside). Prior stop was $10.05. Stop-loss: $10.05.

What are the risks of investing in ARDT?

Target reached (-0.9% upside); Risk below floor (2.7 < 3.0).

Is ARDT overvalued or undervalued?

Ardent Health, Inc. trades at a P/E of 11.4 (forward 8.2). TrendMatrix value score: 8.2/10. Verdict: Sell.

What do analysts say about ARDT?

18 analysts cover ARDT with a consensus score of 3.9/5. Average price target: $12.

What does Ardent Health, Inc. do?Ardent Health operates 30 acute care hospitals and more than 280 additional sites of care across eight mid-sized urban...

Ardent Health operates 30 acute care hospitals and more than 280 additional sites of care across eight mid-sized urban markets in Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas, often through majority-owned joint ventures with academic medical centers, non-profit health systems, and physician groups. The company earns revenue from inpatient and ambulatory patient care reimbursed by Medicare, Medicaid, and private third-party payors, with private payors accounting for 44.3% of 2025 revenue, and named Dave Caspers as President and CEO in June 2026 after Martin Bonick's departure.

Related stocks: NUTX (Nutex Health Inc.) · SRTA (Strata Critical Medical, Inc.) · ASTH (Astrana Health Inc.) · UHS (Universal Health Services, Inc.) · EHC (Encompass Health Corporation)
Home Stocks ARDT

Latest news

Latest News

Investing.com Australia62d ago
Investing.com Canada62d agoAnalyst
Yahoo Finance63d ago
MarketBeat70d agoEarnings
Investing.com Canada56d ago
Quiver Quantitative63d ago
Marketscreener.com63d agoEarnings
Marketscreener.com63d agoEarnings
Seeking Alpha59d agoEarnings
Sahm60d ago
Simplywall.st60d ago
MarketBeat60d agoEarnings
ACCESS Newswire61d agoLegal
TradingView67d agoEarnings
MarketBeat67d ago
Benzinga34d ago
Benzinga35d ago
Benzinga35d agoLeadership Change
Benzinga54d agoProduct
Benzinga61d agoAnalyst
Loading more...